(Q42271842)

19 October 2017

title

Razoxane (ICRF 159) in the treatment of psoriasis (English)

1 reference

19 October 2017

Atherton DJ

1

1 reference

19 October 2017

Wells RS

series ordinal

2

1 reference

19 October 2017

Laurent MR

series ordinal

3

1 reference

19 October 2017

Williams YF

series ordinal

4

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 March 1980

1 reference

British Journal of Dermatology

19 October 2017

published in

1 reference

19 October 2017

volume

102

1 reference

19 October 2017

issue

3

1 reference

19 October 2017

page(s)

307-317

1 reference

Metabolic and ultrastructural studies in a patient with pustular psoriasis (von Zumbusch).

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.1980.TB08145.X

The bioavailability in man of ICRF-159 a new oral antineoplastic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.1980.TB08145.X

Cumulative Cytostatic Effect of ICRF 159

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.1980.TB08145.X

Mode of Action of the Cytostatic Agent ‘ICRF 159’

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.1980.TB08145.X

An Improved Bacterial Test System for the Detection and Classification of Mutagens and Carcinogens

21 January 2018

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1073/PNAS.70.3.782

Identifiers

DOI

10.1111/J.1365-2133.1980.TB08145.X

1 reference

19 October 2017

1 reference